Erratum: lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma (Oncology Letters (2021) 21 (455) DOI: 10.3892/ol.2021.12716)

HIDEHARU YAMADA, MASANOBU TAKAHASHI, MUNENORI WATANUKI, MIKA WATANABE, SAKURA HIRAIDE, KEN SAIJO, KEIGO KOMINE, CHIKASHI ISHIOKA

研究成果: Comment/debate査読

抄録

Subsequently to the publication of the above paper, the authors realized that the layouts of Tables I and III had been presented incorrectly, and that they had overlooking acknowledging researchers who had provided them with the cell lines in the Acknowledgements section of the paper. Consequently, the correctly organized versions of Tables I and 3 are shown on the subsequent pages. Concerning the oversight with the Acknowledgements section, this section of the declarations should be changed to the following (added text is highlighted in bold):. (Table Presented).

本文言語English
論文番号698
ジャーナルOncology Letters
22
4
DOI
出版ステータスPublished - 2021 10

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究

フィンガープリント

「Erratum: lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma (Oncology Letters (2021) 21 (455) DOI: 10.3892/ol.2021.12716)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル